Exchange: NYSEMkt·Updated 07:54 PM EDT

NNVC News

News
all
press releases
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers   New York, NY – September 15, 2026 – Market News Updates News Commentary – The antiviral market is entering a period where the need for new treatments is becoming impossible […] The post A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat appeared first on Financial News Media.
Financial News Media
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola
The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.
Stocktwits
NNVC Stock Up 17% Today: What’s Driving The Rally?
U.S. FDA granted Orphan Drug Designation to NanoViricides’ broad-spectrum antiviral candidate NV-387 for the treatment of measles.
Stocktwits

Advertisement|Remove ads.